Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder)1. The program is limited to financially eligible patients covered by commercial insurance.
A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.
Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”
+myBinderRelated Content
-
Pfizer’s Kevin Williams to Pen Health Column on Sickle Cell Disease for the Black PressDr. Kevin Williams, the Chief Medical Of...
-
Darryl Watkins Stays Positive in Spite of Sickle Cell DiseaseDarryl Watkins has the HbSS variant of s...
-
Global Alliance of Sickle Cell Disease OrganizationsGlobal Alliance of Sickle Cell Disease O...
-
Today’s Faces of Sickle Cell Disease: Pat Corley, RNIn 1979, while she was volunteering at a...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
Allan F. Platt, MMSc, PA-C, DFAAPAAllan Platt has served as co-founder and...
-
Pfizer and National Newspaper Publishers to Raise Awareness About Sickle Cell DiseasePfizer and the National Newspaper Publis...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.